In-situ nanofiber material for enhancing tumor immunogenicity and preparation method and application thereof
By preparing nanofiber patches combining Anlotinib and GeP nanosheets with PLLA, and then combining NIR irradiation with aPD-L1 treatment, the problems of poor drug penetration and immunosuppression in HCC treatment were solved, thereby achieving enhanced tumor immunogenicity and tumor killing effects.
CN117017951BActive Publication Date: 2026-07-07THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
- Filing Date
- 2023-08-02
- Publication Date
- 2026-07-07
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
The application belongs to the technical field of biomedical polymer materials, and discloses in-situ nanofiber materials for enhancing tumor immunogenicity, and a preparation method and application thereof. The application constructs in-situ nanofiber loaded with a degradable carrier, a molecular targeted drug Anlotinib and Gep nanosheet, and then the in-situ nanofiber is made into a patch and directly applied to a tumor lesion, and is combined with NIR assisted irradiation and aPD-L1 treatment. The application not only improves the delivery efficiency of AL through local administration, and overcomes the problem of low efficiency of systemic administration through a nanocarrier, but also takes inhibition of excessive growth of HCC blood vessels as a starting point, combines PTT and ICB treatment, and enhances the immunogenicity of a residual tumor after a three-mode combined treatment cascade, and enhances an immune response. Meanwhile, the application has the advantages of simple components, flexible formula, easy preparation and the like. Therefore, the in-situ nanofiber material has wide practical application value in the field of tumor treatment.
Need to check novelty before this filing date? Find Prior Art